Modeling congenital brain malformations with brain organoids: a narrative review

Ji, Xiao-Shan; Ji, Xiaoli; Xiong, Man; Zhou, Wenhao

doi:10.21037/tp-22-239

Cited by 1 publication

(1 citation statement)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies support the potential of human brain organoids that have been summarized by Amin and Paşca (2018) . They emphasized a few models of neurodevelopmental disorders such as congenital lissencephaly ( Ji et al, 2023 ), brain folding disorders ( Scott and Huang, 2022 ), Seckel syndrome ( Ichisima et al, 2019 ), ischemia ( Wang et al, 2020 ), etc. Ultimately, understanding complexity of nervous systems diseases and pathophysiological of human brains remain challenging despite current progress in neuroscience research.…”

Section: Ipsc-based Organoids Of Neurological Diseasesmentioning

confidence: 99%

Development of brain organoid technology derived from iPSC for the neurodegenerative disease modelling: a glance through

Jusop

Thanaskody

Tye

et al. 2023

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Neurodegenerative diseases are adult-onset neurological conditions that are notoriously difficult to model for drug discovery and development because most models are unable to accurately recapitulate pathology in disease-relevant cells, making it extremely difficult to explore the potential mechanisms underlying neurodegenerative diseases. Therefore, alternative models of human or animal cells have been developed to bridge the gap and allow the impact of new therapeutic strategies to be anticipated more accurately by trying to mimic neuronal and glial cell interactions and many more mechanisms. In tandem with the emergence of human-induced pluripotent stem cells which were first generated in 2007, the accessibility to human-induced pluripotent stem cells (hiPSC) derived from patients can be differentiated into disease-relevant neurons, providing an unrivaled platform for in vitro modeling, drug testing, and therapeutic strategy development. The recent development of three-dimensional (3D) brain organoids derived from iPSCs as the best alternative models for the study of the pathological features of neurodegenerative diseases. This review highlights the overview of current iPSC-based disease modeling and recent advances in the development of iPSC models that incorporate neurodegenerative diseases. In addition, a summary of the existing brain organoid-based disease modeling of Alzheimer’s disease was presented. We have also discussed the current methodologies of regional specific brain organoids modeled, its potential applications, emphasizing brain organoids as a promising platform for the modeling of patient-specific diseases, the development of personalized therapies, and contributing to the design of ongoing or future clinical trials on organoid technologies.

show abstract